TD Asset Management Inc. Sells 43,165 Shares of Annexon, Inc. (NASDAQ:ANNX)

TD Asset Management Inc. lessened its stake in shares of Annexon, Inc. (NASDAQ:ANNX – Get Rating) by 50.1% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 42,908 shares of the company’s stock after selling 43,165 shares during the period. TD Asset Management Inc.’s holdings in Annexon were worth $117,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of ANNX. Eventide Asset Management LLC raised its position in Annexon by 12.6% in the 4th quarter. Eventide Asset Management LLC now owns 2,850,000 shares of the company’s stock valued at $32,747,000 after purchasing an additional 318,372 shares during the last quarter. Pictet Asset Management SA raised its position in Annexon by 33.5% in the 4th quarter. Pictet Asset Management SA now owns 2,158,684 shares of the company’s stock valued at $24,803,000 after purchasing an additional 541,450 shares during the last quarter. Alliancebernstein L.P. raised its position in Annexon by 21.7% in the 4th quarter. Alliancebernstein L.P. now owns 2,090,355 shares of the company’s stock valued at $24,018,000 after purchasing an additional 373,074 shares during the last quarter. Northern Trust Corp raised its position in Annexon by 2.5% in the 4th quarter. Northern Trust Corp now owns 294,186 shares of the company’s stock valued at $3,380,000 after purchasing an additional 7,252 shares during the last quarter. Finally, Schroder Investment Management Group raised its position in Annexon by 2.8% in the 4th quarter. Schroder Investment Management Group now owns 84,493 shares of the company’s stock valued at $971,000 after purchasing an additional 2,262 shares during the last quarter.

Annexon Stock Performance

NASDAQ ANNX opened at $5.77 on Friday. The stock has a fifty day moving average of $4.89 and a 200-day moving average of $4.00. The stock has a market capitalization of $274.76 million, a P/E ratio of -1.53 and a beta of 0.67. Annexon, Inc. has a 52 week low of $2.06 and a 52 week high of $23.61.

Want More Great Investing Ideas?

Annexon (NASDAQ:ANNX – Get Rating) last released its earnings results on Monday, August 8th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.01). During the same quarter in the prior year, the business earned ($0.82) earnings per share. Equities research analysts forecast that Annexon, Inc. will post -3.52 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Muneer A. Satter acquired 2,453,988 shares of the firm’s stock in a transaction that occurred on Thursday, July 7th. The stock was acquired at an average cost of $3.84 per share, with a total value of $9,423,313.92. Following the completion of the purchase, the director now directly owns 4,408,966 shares in the company, valued at $16,930,429.44. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ANNX. Cantor Fitzgerald cut their price objective on Annexon from $27.00 to $22.00 and set an “overweight” rating for the company in a research report on Tuesday, August 16th. HC Wainwright cut their price objective on Annexon from $40.00 to $30.00 in a research report on Tuesday, May 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $28.75.

About Annexon

(Get Rating)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.